ATE385799T1 - Zusammensetzung einer natriumkanal-blockierenden verbindung - Google Patents

Zusammensetzung einer natriumkanal-blockierenden verbindung

Info

Publication number
ATE385799T1
ATE385799T1 AT01997312T AT01997312T ATE385799T1 AT E385799 T1 ATE385799 T1 AT E385799T1 AT 01997312 T AT01997312 T AT 01997312T AT 01997312 T AT01997312 T AT 01997312T AT E385799 T1 ATE385799 T1 AT E385799T1
Authority
AT
Austria
Prior art keywords
sodium channel
composition
blocking compound
channel blocking
region
Prior art date
Application number
AT01997312T
Other languages
English (en)
Inventor
Yuhong Kang
Frank Shum
Original Assignee
Nanning Maple Leaf Pharmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanning Maple Leaf Pharmaceuti filed Critical Nanning Maple Leaf Pharmaceuti
Application granted granted Critical
Publication of ATE385799T1 publication Critical patent/ATE385799T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT01997312T 2000-11-22 2001-11-19 Zusammensetzung einer natriumkanal-blockierenden verbindung ATE385799T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNB001326724A CN1236773C (zh) 2000-11-22 2000-11-22 用于镇痛、麻醉或治疗药物依赖性的制剂

Publications (1)

Publication Number Publication Date
ATE385799T1 true ATE385799T1 (de) 2008-03-15

Family

ID=4595311

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01997312T ATE385799T1 (de) 2000-11-22 2001-11-19 Zusammensetzung einer natriumkanal-blockierenden verbindung

Country Status (8)

Country Link
US (1) US6559154B2 (de)
EP (2) EP1335747B1 (de)
JP (1) JP2004513186A (de)
CN (1) CN1236773C (de)
AT (1) ATE385799T1 (de)
AU (1) AU2002221491A1 (de)
DE (1) DE60132798T2 (de)
WO (1) WO2002041915A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1284536C (zh) * 2000-09-18 2006-11-15 威克斯医药有限公司 河豚毒素或蛤蚌毒素及其类似物在制备用于全身镇痛的镇痛药中的应用
CN1269482C (zh) * 2001-05-18 2006-08-16 威克斯医药有限公司 钠离子通道阻断剂和阿片类镇痛剂在制备用于对哺乳动物进行协同镇痛的药物中的应用
HUP0402268A2 (hu) * 2001-11-15 2005-02-28 Micro Algae Corp. 3,4-propinoperhidropurinokat tartalmazó gyógyászati kompozíciók és alkalmazásuk ingerületátvitel gátlására
CN1568999A (zh) * 2003-07-14 2005-01-26 南宁枫叶药业有限公司 稳定的医药用河豚毒素冷冻干燥制剂
AU2005244096B2 (en) * 2004-05-07 2011-03-17 Algenis Spa Transdermal administration of phycotoxins
CA2607589A1 (en) * 2004-05-07 2005-11-24 Phytotox Limited Methods of treating wounds with gonyautoxins
AU2005287511A1 (en) * 2004-09-21 2006-03-30 Wex Medical Limited Tetrodotoxin and its derivatives for the treatment of central-nervously derived neuropathic pain
KR20070092698A (ko) * 2004-09-22 2007-09-13 라보라토리오스 델 드라. 에스테브.에스.에이. 말초 신경적으로 유발된 신경병증성 통증을 치료하기 위한테트로도톡신 및 그것의 유도체
WO2006101629A2 (en) 2005-02-17 2006-09-28 Vertex Pharmaceuticals Incorporated SODIUM CHANNEL PROTEIN TYPE III α-SUBUNIT SPLICE VARIANT
CA2619668A1 (en) * 2005-08-25 2007-03-01 Edge Renfeng Wang Use of sodium channel blockers for the management of musculoskeletal pain
WO2007025212A2 (en) * 2005-08-25 2007-03-01 Wex Pharmaceuticals, Inc. Use of sodium channel blockers for the treatment of visceral pain or pain caused by cancer treatment
US20080200408A1 (en) * 2005-09-30 2008-08-21 Mccormack Kenneth Deletion mutants of tetrodotoxin-resistant sodium channel alpha subunit
US7972813B2 (en) * 2005-09-30 2011-07-05 Vertex Pharmaceuticals Incorporated Tetrodotoxin-resistant sodium channel alpha subunit
EP2012774A1 (de) 2006-03-27 2009-01-14 Wex Pharmaceuticals, Inc Verwendung von natriumkanalblockern zur behandlung von neuropathischen schmerzen infolge von chemotherapie
US8658699B2 (en) 2008-05-19 2014-02-25 Massachusetts Institute Of Technology Chemical permeation enhancers enhance nerve blockade by toxins
CN101352422B (zh) * 2008-09-17 2011-04-20 厦门朝阳生物工程有限公司 河豚毒素冻干粉针制剂及其制备方法
US8952152B2 (en) 2009-03-24 2015-02-10 Proteus S.A. Methods for purifying phycotoxins, pharmaceutical compositions containing purified phycotoxins, and methods of use thereof
SI2968225T1 (sl) 2013-03-15 2019-05-31 The Children's Medical Center Corporation Kombinirane formulacije neosaksitoksina za podaljšano lokalno anestezijo

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3898339A (en) * 1973-08-14 1975-08-05 Astra Pharma Prod Spinal anesthesia using small amounts of tetrodotoxin or desoxytetrodotoxin
US4029793A (en) 1973-06-12 1977-06-14 Astra Pharmaceutical Products, Inc. Synergistic local anesthetic compositions
US4022899A (en) 1973-06-12 1977-05-10 Astra Pharmaceutical Products, Inc. Synergistic local anesthetic compositions
JPH09510221A (ja) * 1994-03-17 1997-10-14 ナンニン メープル リーフ ファーマスーティカル カンパニー リミテッド 薬物依存からの離脱のためのアミノ水素化キナゾリン化合物およびそれらの誘導体の用途
CN1081034C (zh) * 1997-03-07 2002-03-20 潘心富 一种双胍基氢化嘌呤环类化合物的戒毒药
US6030974A (en) * 1997-04-02 2000-02-29 The Regents Of The University Of California Method of anesthesia
WO1998051290A2 (en) * 1997-05-16 1998-11-19 Children's Medical Center Corporation Local anesthetic formulations comprising a site 1 sodium channel blocker combined with a second active agent
CN1284536C (zh) 2000-09-18 2006-11-15 威克斯医药有限公司 河豚毒素或蛤蚌毒素及其类似物在制备用于全身镇痛的镇痛药中的应用
CN1240702C (zh) 2000-09-18 2006-02-08 威克斯医药有限公司 高获得率提取替曲朵辛的方法
CN1203857C (zh) 2000-09-18 2005-06-01 威克斯医药有限公司 局部麻醉与镇痛的新方法

Also Published As

Publication number Publication date
EP1335747A4 (de) 2005-10-12
EP1335747B1 (de) 2008-02-13
US6559154B2 (en) 2003-05-06
WO2002041915A1 (en) 2002-05-30
DE60132798T2 (de) 2009-02-12
EP1335747A1 (de) 2003-08-20
EP1930027A2 (de) 2008-06-11
US20020119987A1 (en) 2002-08-29
CN1236773C (zh) 2006-01-18
EP1930027A3 (de) 2008-06-18
AU2002221491A1 (en) 2002-06-03
DE60132798D1 (de) 2008-03-27
JP2004513186A (ja) 2004-04-30
CN1353990A (zh) 2002-06-19

Similar Documents

Publication Publication Date Title
DE60132798D1 (de) Zusammensetzung einer natriumkanal-blockierenden verbindung
PT1413582E (pt) Pirrolobenzodiazepinas dimericas
TR200200579T2 (tr) Amino-tirazolpiridin türevleri.
DK1301436T3 (da) Fremgangsmåder til syntese af et oxidationsmiddel samt dets anvendelse
BR0209242A (pt) Aminopolidiorganossiloxanos amido-funcionais
HN1999000125A (es) Nuevos derivados sustituidos del pirazol
PL360092A1 (en) Structures and compositions increasing the stability of peroxide actives
ATE403429T1 (de) Spiropyrazol-verbindungen
DK1040119T3 (da) Hemiasterlinanaloger
HK1045990A1 (en) Novel derivatives and analogues of galanthamin.
HK1029754A1 (en) Formulations for protection of peg-interferon alpha conjugates.
DE60112960D1 (de) Kondensierte pyridoindolderivate
SE9801494D0 (sv) Novel use
BG106316A (en) Ambroxol-containing lozenge
HUP0202592A2 (hu) Lazofoxifen transzdermális adagolása
DE60121048D1 (de) PYRAZINOi1'2':1,6öPYRIDOi3,4-BöINDOLDERIVATE
BG105964A (en) C(10) carbonate substituted taxanes and their use as antitumor agents
BR0114065A (pt) Triazolo-epotilonas
DK1177191T3 (da) Substituerede benzimidazoler, fremstilling og anvendelse deraf som midler til bekæmpelse af parasitiske protozoer
GT199900037A (es) Nuevas composiciones herbicidas.
TR200003203T2 (tr) Karboksaldehitin saflaştırılması
DK1052995T3 (da) Farmaceutisk præparat til nasal indgivelse af thiocolchicosid
ATE249204T1 (de) Spray, enthaltend ubichinon qn
BR8002856U (pt) Televisão relógio
BR0113202A (pt) Compostos de trioxepano

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties